Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
Apple
AAPL
|
$975M |
| 2 |
Amazon
AMZN
|
$708M |
| 3 |
UnitedHealth
UNH
|
$634M |
| 4 |
Rivian
RIVN
|
$504M |
| 5 |
TJX Companies
TJX
|
$483M |
Top Sells
| 1 |
Meta Platforms (Facebook)
META
|
$1.1B |
| 2 |
NVIDIA
NVDA
|
$814M |
| 3 |
L3Harris
LHX
|
$714M |
| 4 |
Zurn Elkay Water Solutions
ZWS
|
$503M |
| 5 |
Texas Instruments
TXN
|
$468M |
Sector Composition
| 1 | Technology | 32.52% |
| 2 | Healthcare | 18.41% |
| 3 | Consumer Discretionary | 11.42% |
| 4 | Financials | 9.67% |
| 5 | Industrials | 8.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2526
TrueCar
TRUE
$187M
| $65K | ﹤0.01% |
+19,005
| New | +$65K |
|
|
AUD
2527
DELISTED
Audacy, Inc.
AUD
| $64K | ﹤0.01% |
25,007
+12,569
| +101% | +$32.2K |
|
2528
Viking Therapeutics
VKTX
$2.98B
| $62K | ﹤0.01% |
+13,409
| New | +$62K |
|
2529
Geron
GERN
$880M
| $60K | ﹤0.01% |
49,025
+24,741
| +102% | +$30.3K |
|
2530
RPC Inc
RES
$1.06B
| $60K | ﹤0.01% |
+13,154
| New | +$60K |
|
2531
New Oriental
EDU
$7.98B
| $57K | ﹤0.01% |
2,699
| – | – |
|
2532
Standard BioTools
LAB
$493M
| $56K | ﹤0.01% |
+14,407
| New | +$56K |
|
|
CLVS
2533
DELISTED
Clovis Oncology, Inc.
CLVS
| $55K | ﹤0.01% |
20,270
+10,239
| +102% | +$27.8K |
|
|
ZOM
2534
DELISTED
Zomedica Corp.
ZOM
| $55K | ﹤0.01% |
177,068
+88,139
| +99% | +$27.4K |
|
|
BDSI
2535
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $54K | ﹤0.01% |
+17,444
| New | +$54K |
|
|
SDC
2536
DELISTED
SmileDirectClub, Inc. Class A Common Stock
SDC
| $49K | ﹤0.01% |
20,830
+10,489
| +101% | +$24.7K |
|
2537
Alaunos Therapeutics
TCRT
$4.27M
| $48K | ﹤0.01% |
290
+146
| +101% | +$24.2K |
|
2538
Lexicon Pharmaceuticals
LXRX
$389M
| $46K | ﹤0.01% |
+11,786
| New | +$46K |
|
2539
GoHealth
GOCO
$78.2M
| $38K | ﹤0.01% |
+673
| New | +$38K |
|
|
EPZM
2540
DELISTED
Epizyme, Inc
EPZM
| $36K | ﹤0.01% |
+14,529
| New | +$36K |
|
|
ALLK
2541
DELISTED
Allakos
ALLK
| – | – |
-983,329
| Closed | -$104M |
|
2542
Allogene Therapeutics
ALLO
$246M
| – | – |
-7,795
| Closed | -$200K |
|
2543
Arvinas
ARVN
$559M
| – | – |
-3,608
| Closed | -$296K |
|
2544
Asana
ASAN
$3.46B
| – | – |
-6,459
| Closed | -$671K |
|
2545
JPMorgan BetaBuilders Developed Asia Pacific-ex Japan ETF
BBAX
$5.43B
| – | – |
-166,591
| Closed | -$9.03M |
|
2546
Bilibili
BILI
$9.29B
| – | – |
-13,268
| Closed | -$878K |
|
2547
CNA Financial
CNA
$13.2B
| – | – |
-26,069
| Closed | -$1.09M |
|
2548
Copa Holdings
CPA
$4.86B
| – | – |
-17,857
| Closed | -$1.45M |
|
2549
DraftKings
DKNG
$23.5B
| – | – |
-20,832
| Closed | -$1M |
|
2550
Doximity
DOCS
$12.8B
| – | – |
-71,076
| Closed | -$5.74M |
|